Post‐Liver Transplantation–Burkitt Lymphoma in Children: A Single‐Center Study of Clinical Characteristics, Treatment, and Outcomes
Pediatric Transplantation · 2025
DOI: 10.1111/petr.70027 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pediatric Transplantation, 2025. Verfasst von Tianran Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: First Central Clinical School, Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Liver Transplantation, Burkitt Lymphoma, Postoperative Complications. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Key Research and Development Program of China.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Post‐liver transplantation–Burkitt lymphoma (PLT‐BL) is an aggressive and life‐threatening complication after pediatric liver transplantation. The research on the disease characteristics, treatment, and prognosis of pediatric PLT‐BL is limited.
Methods
A retrospective, observational study was performed to analyze the disease characteristics, treatment, and outcomes in 12 pediatric liver transplant (LT) recipients diagnosed with PLT‐BL.
Results
The medium time from liver transplantation to diagnosis was 32.71 months (range, 25.78–37.85 months). All patients (100%) tested positive for EBV viremia at diagnosis. Abdomen and peripheral lymph nodes were the most frequently involved sites (11 [91.66%] and 10 [83.33%], respectively). Three pediatric patients were diagnosed as relapsed or refractory PLT‐BL and treated with chimeric antigen receptor (CAR) T‐cell therapy, and two of them achieved complete remission (CR). Nine patients were alive with CR at the last follow‐up. Three deaths were attributed to progression and tumor lysis syndrome, characterized by significantly elevated lactate dehydrogenase (LDH) levels ( p = 0.027), more advanced tumor stages ( p = 0.045), and an increased number of involved sites ( p = 0.009). With a median follow‐up of 2.7 years after diagnosis, the event‐free survival (EFS) and overall survival (OS) rates for PLT‐BL patients were 66.7% and 74.1%, respectively. In four patients, immunosuppression was successfully withdrawn and they maintained tolerance status.
Conclusion
Elevated LDH levels, more advanced tumor stages, and increased number of involved sites are potentially associated with poor outcome. Immunosuppression withdrawal is a safe and feasible approach for PLT‐BL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- First Central Clinical School, Tianjin Medical University, Tianjin, China.
- Department of Liver Transplantation, Organ Transplantation Center, Tianjin First Central Hospital, Tianjin, China.
- Tianjin Key Laboratory of Organ Transplantation, Tianjin, China.
ORCID-Profile: Tianran Chen, Chao Sun, Kai Wang, Wei Gao
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Chen, T., Zheng, W., Wang, R., Dong, C., Sun, C., Wang, K., Han, C., Wei, X., & Gao, W. (2025). Post‐Liver Transplantation–Burkitt Lymphoma in Children: A Single‐Center Study of Clinical Characteristics, Treatment, and Outcomes. Pediatric Transplantation. https://doi.org/10.1111/petr.70027
Vancouver
Chen T, Zheng W, Wang R, Dong C, Sun C, Wang K, et al. Post‐Liver Transplantation–Burkitt Lymphoma in Children: A Single‐Center Study of Clinical Characteristics, Treatment, and Outcomes. Pediatric Transplantation. 2025. doi:10.1111/petr.70027
BibTeX
@article{Chen2025,
author = {Chen, Tianran and Zheng, Weiping and Wang, Ruofan and Dong, Chong and Sun, Chao and Wang, Kai and Han, Chao and Wei, Xinzhe and Gao, Wei},
title = {Post‐Liver Transplantation–Burkitt Lymphoma in Children: A Single‐Center Study of Clinical Characteristics, Treatment, and Outcomes},
journal = {Pediatric Transplantation},
year = {2025},
doi = {10.1111/petr.70027}
}
EUVIMED